Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

By D. Mccarey, I. McInnes, R. Madhok, R. Hampson, O. Scherbakov, Ian Ford, H. Capell, N. Sattar. The Lancet, 2004

852 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. (2008, background): “Furthermore, statins appear to have therapeutic benefits in diseases that are unrelated to elevated serum cholesterol levels, such as rheumatologic diseases [19] and ischemic stroke [1].”
Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review (2008, background): “There are initial reports of reductions in circulating IL-6 concentrations in randomised trials of statins, although these agents have other effects, notably lowering low-density lipoprotein cholesterol [45–47].”
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update (2016, background): “The second principle indicates the responsibility of the rheumatologist for coordinating CVD risk management in patients with IJD, whereas the last principle aims to put this recommendation update more in line with other (EULAR) recommendations.”